Measurement of outcomes from medical or surgical interventions is part of good practice, but publication of individual doctors' results remains controversial. The authors discuss this issue in the context of cardiothoracic surgery

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC514215PMC
http://dx.doi.org/10.1136/bmj.329.7463.450DOI Listing

Publication Analysis

Top Keywords

legacy bristol
4
bristol public
4
public disclosure
4
disclosure individual
4
individual surgeons'
4
surgeons' measurement
4
measurement outcomes
4
outcomes medical
4
medical surgical
4
surgical interventions
4

Similar Publications

Interventions to prevent surgical site infection in adults undergoing cardiac surgery.

Cochrane Database Syst Rev

December 2024

Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.

Article Synopsis
  • * It outlines the objectives of a study aimed at assessing the effectiveness of various interventions before, during, and after surgery to prevent SSIs and evaluate their impact on patient outcomes.
  • * The study includes a comprehensive search for randomized controlled trials (RCTs) related to SSI prevention in adult cardiac surgery and aims to establish a clearer standard of care for managing these infections.
View Article and Find Full Text PDF

Association of organ procurement organization volume with Centers for Medicare and Medicaid Services performance evaluations.

Am J Transplant

November 2024

Division of Transplant Surgery, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA; Colorado Center for Transplantation Care (CCTCARE), Research and Education, Division of Transplant Surgery, Department of Surgery, Anschutz Medical Campus, University of Colorado, Aurora, Colorado, USA; Department of Epidemiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Electronic address:

Under 2020 Centers for Medicare and Medicaid Services (CMS) conditions of coverage, Organ Procurement Organizations (OPOs) will be decertified if their 95% upper confidence limit for donation or transplant rate falls below the previous year's median (tier 3) and must recompete if either is below the 75th percentile (tier 2). This study aimed to examine the associations of CMS metrics with OPO volume and evaluate an alternate observed-to-expected tiering system using simulation analysis and CMS's OPO public report. In 2021, CMS tier 3 and 2 OPOs had significantly larger volumes than tier 1 OPOs (median = 2042 vs 2124 vs 1003; P = .

View Article and Find Full Text PDF

Diagnosis and management of subungual and periungual verruca: A clinical review.

J Am Acad Dermatol

November 2024

Department of Dermatology, Weill Cornell Medicine, New York, New York. Electronic address:

Nail unit verruca is the most common nail tumor encountered in clinical practice and may be highly distressing to patients due to reduced functionality, cosmesis, and stigmatization. Subungual and periungual verrucae present a challenge for treatment compared to cutaneous warts of other sites and recurrence rates are high. The risk of spread to other skin and mucosal areas inherent to all warts may be increased given location on the fingertips.

View Article and Find Full Text PDF

Despite some progress, universal access to safe water, sanitation and hygiene (WASH) by 2030-a remit of Sustainable Development Goal 6-remains a distant prospect in many countries. Policy-makers and implementers of the WASH sector are challenged to track a new path. This research aimed to identify core orienting themes of the sector, as legacies of past processes, which can provide insights for its future.

View Article and Find Full Text PDF

Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort study.

Clin Exp Med

October 2024

Department of Dermatology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

Metastatic uveal melanoma (mUM) is associated with poor prognosis. Ipilimumab/nivolumab has shown antitumor efficacy in phase II studies. Tebentafusp resulted in longer overall survival (OS) compared to investigator`s choice in a phase III study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!